Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE + Tislelizumab + Lenvatinib vs GEMCIS + Tislelizumab in Unresectable Intrahepatic Cholangiocarcinoma
NCT07691515Phase 3Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Sep 2026
- Primary completion
- Jan 2030
- Countries
- 1
01
Overview
A Phase 3 trial of lenvatinib, tislelizumab in intrahepatic cholangiocarcinoma (ICC), sponsored by Zhejiang Cancer Hospital. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
lenvatinibtislelizumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT07691515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07691515.